本页面由Tiger Trade Technology Pte. Ltd.提供服务

众巢医学

1.84
+0.02001.10%
盘后1.840.0030+0.16%16:45 EDT
成交量:1.52万
成交额:2.84万
市值:707.34万
市盈率:-1.21
高:1.91
开:1.82
低:1.71
收:1.82
52周最高:12.18
52周最低:1.45
股本:384.42万
流通股本:233.20万
量比:0.77
换手率:0.65%
股息:- -
股息率:- -
每股收益(TTM):-1.5200
每股收益(LYR):-0.9885
净资产收益率:-5.93%
总资产收益率:-2.90%
市净率:0.35
市盈率(LYR):-1.86

数据加载中...

2026/01/15

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2025/08/22

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/07/09

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/06/21

SEC问询函

Form CORRESP - Correspondence
2025/06/07

SEC问询函

Form CORRESP - Correspondence
2025/05/20

SEC问询函

Form CORRESP - Correspondence
2025/05/07

SEC问询函

Form CORRESP - Correspondence
2025/04/25

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/02/27

SEC问询函

Form CORRESP - Correspondence
2024/04/30

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/05/12

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/05/09

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/05/21

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/04/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/05/08

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/01

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/23

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/02

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/26

超过5%披露

General statement of acquisition of beneficial ownership
2020/02/26

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]